Last updated: 2026-09-06 01:45:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
SpyGlass Pharma, Inc. (SGP) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $29,00, with a market capitalisation of $945,91M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17,06 to $32,44. This page covers its latest market performance, valuation, price trends and company information.
$945,91M | |
$28,81 | |
$35,15 | |
$11,97 | |
$28,99 | |
68,42K | |
-- | |
-- | |
$32,44 | |
$17,06 | |
-- | |
-- |
SpyGlass Pharma, Inc. (SGP) last closed at $28,99 as of 2026-09-04 23:31:00, unchanged from the previous close of $28,99.
During the latest regular trading session, SGP traded between $11,97 and $35,15, with a volume of 68,42K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, SpyGlass Pharma, Inc. (SGP) moved from $26,42 to $29,00, representing a gain of 9,75% ($2,58).
The stock traded between $28,13 and $29,50 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 82,74 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 77,6%
SGP is currently trading at $29,00, placing it 77,6% of the way from its 52-week low of $17,06 to its 52-week high of $32,44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 65 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of SpyGlass Pharma, Inc. (SGP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.